摘要: In contrast to the improvements in overall survival for most other gastrointestinal tract cancers, 5-yr of patients with pancreatic cancer sits at a dismal 4% (1), suggesting that there has been no significant improvement early diagnosis or therapy. 1998, an estimated 27,600 new cases will be diagnosed (1). This disease is fourth leading cause death men and fifth women.
springer.com
springerlink.com参考文章(93)
R P Whitehead, J Jacobson, T D Brown, S A Taylor, G R Weiss, J S Macdonald, Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology. ,vol. 15, pp. 2414- 2419 ,(1997) , 10.1200/JCO.1997.15.6.2414
B. Glimelius, K. Hoffman, W. Graf, U. Haglund, O. Nyrén, L. Páhlman, P.-O. Sjödén, Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer Annals of Oncology. ,vol. 6, pp. 267- 274 ,(1995) , 10.1093/OXFORDJOURNALS.ANNONC.A059157
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 15, pp. 2403- 2413 ,(1997) , 10.1200/JCO.1997.15.6.2403
S.R. Patel, L.K. Kvols, J. Rubin, M.J. O'Connell, J.H. Edmonson, M.M. Ames, J.S. Kovach, Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Investigational New Drugs. ,vol. 9, pp. 53- 57 ,(1991) , 10.1007/BF00194545
A. Allegretto, R. Lionetto, S. Saccomanno, M. Paganuzzi, M. Onetto, C. Martinoli, G. Rollandi, M. Marugo, L. Fazzuoli, V. Pugliese, LH – RH Analogue Treatment in Adenocarcinoma of the Pancreas: A Phase II Study Oncology. ,vol. 50, pp. 77- 80 ,(1993) , 10.1159/000227152
PA Philip, J Carmichael, K Tonkin, PK Buamah, J Britton, M Dowsett, AL Harris, Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. British Journal of Cancer. ,vol. 67, pp. 379- 382 ,(1993) , 10.1038/BJC.1993.69
Stephen Cullinan, Charles G. Moertel, Harry S. Wieand, Allan J. Schutt, James E. Krook, John F. Foley, Brian D. Norris, Carl G. Kardinal, Loren K. Tschetter, John F. Barlow, A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin Cancer. ,vol. 65, pp. 2207- 2212 ,(1990) , 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y
Steven D. Passik, William S. Breitbart, Depression in patients with pancreatic carcinoma: Diagnostic and treatment issues Cancer. ,vol. 78, pp. 615- 626 ,(1996) , 10.1002/(SICI)1097-0142(19960801)78:3<615::AID-CNCR42>3.0.CO;2-Z
Ronald M. Bukowski, Stanley P. Balcerzak, Robert M. O'Bryan, John D. Bonnet, T. Timothy Chen, Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study Cancer. ,vol. 52, pp. 1577- 1582 ,(1983) , 10.1002/1097-0142(19831101)52:9<1577::AID-CNCR2820520906>3.0.CO;2-8
S. L. Parker, T. Tong, S. Bolden, P. A. Wingo, Cancer statistics, 1997 CA: A Cancer Journal for Clinicians. ,vol. 47, pp. 5- 27 ,(1997) , 10.3322/CANJCLIN.47.1.5